Colony Group’s Cyclerion Therapeutics CYCN Stock Holding History

Colony Group’s Portfolio CYCN Stock Details CYCN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-5,144	Closed	-$44K	–	771
2023 Q1	$44K	Hold	5,144	–	–	﹤0.01%	775
2022 Q4	$68K	Hold	5,144	–	–	﹤0.01%	817
2022 Q3	$88K	Hold	5,144	–	–	﹤0.01%	752
2022 Q2	$57K	Hold	5,144	–	–	﹤0.01%	805
2022 Q1	$114K	Hold	5,144	–	–	﹤0.01%	824
2021 Q4	$177K	Hold	5,144	–	–	﹤0.01%	780
2021 Q3	$316K	Hold	5,144	–	–	0.01%	672
2021 Q2	$401K	Hold	5,144	–	–	0.01%	580
2021 Q1	$287K	Hold	5,144	–	–	0.01%	651
2020 Q4	$315K	Hold	5,144	–	–	0.01%	601
2020 Q3	$626K	Hold	5,144	–	–	0.02%	435
2020 Q2	$608K	Hold	5,144	–	–	0.02%	423
2020 Q1	$273K	Hold	5,144	–	–	0.01%	568
2019 Q4	$280K	Buy	+5,144	New	+$480K	0.01%	651

Other funds holding CYCN

SPC

Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return

MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CAPTRUST Financial Advisors Raleigh, North Carolina $57.3B AUM 18.32% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Colony Group's CYCN Position: Q2 2023 in Review

Colony Group sold out of Cyclerion Therapeutics (CYCN) in Q2 2023, closing a stake of 5,144 shares — an estimated $44K sold.

Colony Group first reported a position in CYCN in Q4 2019 and held it in 14 quarters. The position peaked at $626K in Q3 2020. 18 funds tracked by Wall St. Rank hold CYCN as of Q2 2023.

Colony Group reported no remaining Cyclerion Therapeutics position as of Q2 2023 after selling out during the quarter.
Colony Group sold 5,144 Cyclerion Therapeutics shares in Q2 2023, an estimated $44K.
Colony Group first reported a position in Cyclerion Therapeutics in Q4 2019 and held it in 14 quarters.
Colony Group's Cyclerion Therapeutics position peaked at $626K in Q3 2020.
18 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q2 2023.

Based on Colony Group's 13F filing for Q2 2023, filed 15 Aug 2023.